“In the near-term  Q BioMed Inc(OTCMKTS: QBIO) has multiple shots on goal with respect to market share  revenue and profit in the multi-billion dollar glaucoma market ” says former Piper Jaffray analyst and mutual fund manager Rob Goldman  who now heads up Goldman Small Cap Research